BACE
The most popular current hypothesis is that Alzheimer’s disease (AD) is caused by aggregates of the amyloid peptide (Aβ), which is generated by cleavage of the Aβ protein precursor (APP) by β-secretase (BACE-1) followed by γ-secretase. BACE-1 is a type-I integral membrane glycoprotein with a 21-residue cleavable signal sequence, a large ectodomain of ~434 aa, a single transmembrane domain of ~22 aa and a short cytoplasmic tail of 24 residues. Several post-translational modifications have been reported on BACE-1, including phosphorylation of a serine in the cytoplasmic domain, palmitoylation of three cysteines in the transmembrane/cytoplasmic domain, sulfation of the N-linked oligosaccharides and inclusion of four glycosylation sites in the catalytic domain. BACE-1 cleavage is limiting for the production of Aβ, making it a particularly good drug target for the generation of inhibitors that lower Aβ.
APP is processed by β-secretase to produce Aβ, BACE-1 cleaves APP at the expected sites on its extracellular domains at positions D1 and E11. When cells were transfected with APP lacking the transmembrane domain, they were not cleaved by BACE-1, suggesting that the enzyme is a membrane bound protease, and only cleaves APP when membrane bound.BACE-1 accepts a wide variety of substrates, preferring acidic or polar residues in contrast to other known aspartyl proteases. NF-kB acts as a repressor for BACE-1 transcription in differentiated neuronal cultures and nonactivated glial cultures, but as an activator for BACE-1 in activated astrocytic and Aβ-exposed neuronal cultures. Depletion of PPARγ results in an increase in the levels of the BACE-1 promoter, wherein mutation at PPRE increases the promoter activity. CD147 is a component of the γ secretase complex, and hence the complex may modulate BACE-1 expression. BACE-1 expression was increased in cells stimulated with the M1/M3-selective muscarinic ACh receptor agonist talsaclidine. Protein kinase C activation by phorbol esters led to up regulation of BACE-1.
References
1.Chitra Venugopal,et al. CNS Neurol Disord Drug Targets. 2008 Jun; 7(3): 278–294.
APP is processed by β-secretase to produce Aβ, BACE-1 cleaves APP at the expected sites on its extracellular domains at positions D1 and E11. When cells were transfected with APP lacking the transmembrane domain, they were not cleaved by BACE-1, suggesting that the enzyme is a membrane bound protease, and only cleaves APP when membrane bound.BACE-1 accepts a wide variety of substrates, preferring acidic or polar residues in contrast to other known aspartyl proteases. NF-kB acts as a repressor for BACE-1 transcription in differentiated neuronal cultures and nonactivated glial cultures, but as an activator for BACE-1 in activated astrocytic and Aβ-exposed neuronal cultures. Depletion of PPARγ results in an increase in the levels of the BACE-1 promoter, wherein mutation at PPRE increases the promoter activity. CD147 is a component of the γ secretase complex, and hence the complex may modulate BACE-1 expression. BACE-1 expression was increased in cells stimulated with the M1/M3-selective muscarinic ACh receptor agonist talsaclidine. Protein kinase C activation by phorbol esters led to up regulation of BACE-1.
References
1.Chitra Venugopal,et al. CNS Neurol Disord Drug Targets. 2008 Jun; 7(3): 278–294.
Metabolic Enzyme/Protease
11β-HSD(15)
15-PGDH(1)
ACC(10)
ACE(15)
AChE(47)
Adenylate Cyclase(12)
ALDH(14)
Aldose Reductase(5)
Aminopeptidase(19)
BACE(19)
Casein Kinase(51)
CAT(5)
Cathepsin(9)
CETP(13)
COMT(2)
CPG2(1)
CYPs(6)
Decarboxylase(3)
Dehydrogenase(131)
DGAT(4)
Dopamine beta-hydroxylase(2)
DPP(32)
Elastase(6)
FAAH(28)
Factor Xa(31)
Fatty Acid Synthase(17)
Ftase(2)
FXR(26)
Glucokinase(1)
GSNOR(2)
Guanylate Cyclase(13)
HMGCR(17)
IDH(7)
IDO(20)
IMPDH(2)
LDH(2)
LDL(8)
Lipase(17)
Lipid(12)
MAGL(6)
MAO(72)
MMP(78)
NAMPT(12)
Neprilysin(7)
Other Targets(10)
P450(112)
PAI-1(9)
Phosphatase(95)
Phospholipase(65)
PPAR(115)
Protein Phosphatase/PTP(6)
Renin(8)
Retinoid Receptor(37)
SCD(6)
Steroid Sulfatase (STS)(2)
Thioredoxin(1)
TPH(5)
Transferase(37)
Vitamin(44)
Xanthine Oxidase (XAO)(11)
BACE
-
Atabecestat
产品货号 : M33273
cas no: 1200493-78-2
Atabecestat (JNJ-54861911) 是一种有效的脑渗透型和具有口服活性 β-位淀粉样蛋白前体蛋白裂解酶 1 (BACE1) 抑制剂,可强力降低脑脊液中的 Aβ 蛋白表达降低。Atabecestat 具有耐受性,并具有持续的药代动力学 (PK) 和药效学 (PD) 特征。Atabecestat 有潜力用于阿尔茨海默氏病的研究。 -
Isorubrofusarin-6-O-β-gentiobioside
产品货号 : M29171
cas no: 200127-93-1
Isorubrofusarin-6-O-β-gentiobioside 源自 Cassia obtusifolia Linn 种子,对 AChE 和 BACE1 表现出良好的抑制活性。 -
NB-360
产品货号 : M26324
cas no: 1262857-73-7
NB-360 是一种有效的脑渗透性 BACE1 和 BACE2 抑制剂,对小鼠和人类 BACE1 和 BACE2 的 IC50 分别为 5、5 和 6 nM。 NB-360 比相关的天冬氨酰蛋白酶胃蛋白酶、组织蛋白酶 E 和组织蛋白酶 D 表现出优异的选择性。 -
Elenbecestat
产品货号 : M23546
cas no: 1388651-30-6
Elenbecestat 是一种有效的口服生物利用型和中枢神经系统穿透性 ACE-1 抑制剂,用于治疗阿尔茨海默病。 -
Aloeresin D
产品货号 : M21475
cas no: 105317-67-7
Aloeresin D 是一种天然色酮糖苷,可抑制 β-分泌酶 (BACE1) 活性 (IC50: 39 μM)。